Core Viewpoint - The study reveals the dual role of intratumoral bacteria in regulating tumor immunity, highlighting the significant impact of bacterial invasion on immune responses and tumor recurrence [3][12][18]. Group 1: Tumor Microenvironment and Immune Response - Tumors are categorized as "hot" (immune-activated) or "cold" (immune-suppressive) based on immune cell infiltration and activity, with cold tumors showing insufficient immune response and resistance to immunotherapy [2]. - The presence of intratumoral bacteria is linked to regional immune-suppressive microenvironments, influencing cancer cell behavior and immune cell function through various mechanisms [2][3]. Group 2: Research Findings on Bacteria and Tumor Cells - The research conducted by Cai Shang's team demonstrates that intracellular bacteria activate the cGAS-STING-IL17B signaling pathway in cancer cells, leading to the induction of neutrophils into an immune-suppressive state, thus promoting tumor recurrence [3][12]. - In contrast, extracellular bacteria induce neutrophil subpopulations with anti-tumor functions, activating immune responses that inhibit tumor recurrence [3][12]. Group 3: Methodology and Experimental Models - A strict model for studying intracellular bacteria was established using organoid-bacteria co-culture systems, allowing for the specific investigation of the physiological functions of intracellular bacteria [8]. - In preclinical mouse models, the presence of intracellular bacteria was found to be a key factor in long-term tumor recurrence, with antibiotic treatment reducing recurrence rates significantly from 65% to 6.7% [9]. Group 4: Immune Cell Dynamics - Single-cell RNA sequencing revealed that intracellular bacteria induce neutrophils with myeloid-derived suppressor cell (G-MDSC) characteristics, while extracellular bacteria promote neutrophils with anti-tumor profiles [11][12]. - The cGAS-STING pathway is crucial for the immune reprogramming induced by bacterial invasion, with IL-17B identified as a key mediator in promoting immune suppression [12][14]. Group 5: Clinical Relevance and Future Directions - The study indicates that the strength of bacterial signals within tumor tissues correlates positively with neutrophil infiltration and is associated with poorer prognosis in breast cancer patients [15][19]. - Future research aims to explore targeted strategies for eliminating or limiting intracellular bacterial invasion, optimizing postoperative antibiotic and immunotherapy combinations to prevent tumor recurrence [19].

Core Viewpoint - The research indicates that Paroxetine, a commonly used antidepressant, shows significant efficacy against malignant melanoma, particularly in cases with BRAF V600E mutations that are resistant to targeted therapies [3][5]. Group 1: Research Findings - A study published in Cell Reports Medicine reveals that Paroxetine induces pyroptosis in melanoma cells, a unique mechanism of cell death distinct from traditional apoptosis [3][7]. - The mechanism involves blocking serotonin reuptake, leading to reduced intracellular serotonin levels, which affects DNA repair gene expression and ultimately results in DNA damage accumulation and endoplasmic reticulum stress [7][9]. - Paroxetine is effective against BRAFi/MEKi resistant melanoma due to lower expression of TPH1, making these cells more sensitive to treatment [11]. Group 2: Clinical Implications - The findings suggest multiple clinical benefits: Paroxetine is an already approved drug with known safety, allowing for quicker clinical application [14]. - It serves dual purposes as both an antidepressant and an anti-cancer agent, making it particularly suitable for advanced cancer patients [14]. - The drug offers new options for patients with resistance to targeted therapies and enhances the effectiveness of immune therapies by transforming "cold tumors" into "hot tumors" [11][14].

Core Viewpoint - The article discusses the development of GigaTIME, a multimodal AI framework that enables large-scale modeling of the tumor immune microenvironment (TIME) by connecting cellular morphology and status, overcoming the limitations of traditional costly and low-throughput multiple immunofluorescence (mIF) techniques [4][22]. Group 1: GigaTIME Framework - GigaTIME utilizes a cross-modal translator trained on paired H&E and mIF data from 40 million cells, successfully converting conventional H&E pathology slides into virtual mIF images [4][10]. - The framework has generated virtual mIF images covering 24 cancer types and 306 subtypes, identifying 1,234 associations related to immune activity, tumor invasion, and survival rates, paving the way for scalable data-driven oncology research [4][14]. Group 2: Traditional Techniques vs. AI Breakthroughs - Traditional mIF technology, while rich in protein expression information, is limited by high costs and complex processes, making it difficult for large-scale application [7]. - H&E staining, a cost-effective and widely used method, lacks the ability to directly display protein activity, prompting the need for AI solutions to extract sufficient information from H&E slides [8][9]. Group 3: Clinical Discoveries and Applications - The creation of a virtual population allows for large-scale clinical discoveries, identifying significant protein-biomarker associations across various cancer types [14]. - GigaTIME demonstrates clinical value in patient stratification, with its integrated features outperforming single protein channels in predicting patient survival, highlighting the importance of multi-faceted analysis [19]. Group 4: Future Prospects - Future plans include exploring additional protein channels and integrating cell segmentation models to study intercellular interactions, further elucidating the "grammar" of the tumor microenvironment [21]. - GigaTIME represents a significant advancement in digital pathology, offering researchers tools for large-scale studies of the tumor microenvironment and opening new avenues for precision immuno-oncology [22].

编辑丨王多鱼 排版丨水成文 在许多 " 免疫冷肿瘤 " 中，能够识别肿瘤的特异性 T 细胞十分稀缺，而相当数量状态良好的 T 细胞却因无法识别肿瘤抗原而长期 " 旁 观 " 。与此同时，肿瘤内部又充斥免疫抑制性的巨噬细胞，使得 T 细胞难以维持持续杀伤。 如何让 " 旁观者 " 真正投入战斗，并反向利用巨噬细胞为免疫反应助力，成为破解实体瘤免疫治疗瓶颈的关键。 2025 年 12 月 10 日，上海交通大学医学院附属仁济医院、上海市妇科肿瘤重点实验室 杨帆 研究员团队联合 庄光磊 研究员和 狄文 教授，在 Nature 子刊 Nature Biomedical Engineering 上 发表了题为： A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity 的研究论文。 该研究开发了一种三特异性抗体—— B7H3×CD3×PDL1 ，能够同时结合 T 细胞、肿瘤细胞和巨噬细胞，以增强抗肿瘤免疫。 该研究提出了一条突破传统的肿瘤免疫治疗的新路径——不再依赖稀有的肿瘤特异性 ...

Core Viewpoint - The article discusses the significance of Total Neoadjuvant Therapy (TNT) in the treatment of locally advanced rectal cancer (LARC) and highlights the need for a deeper understanding of the immune remodeling mechanisms involved in its efficacy [3][6]. Group 1: Treatment Strategies and Mechanisms - LARC accounts for over one-third of both incidence and mortality in colorectal cancer, which is the third most common and the second deadliest cancer globally [3]. - Recommended treatment strategies for LARC include TNT or neoadjuvant chemotherapy (nCT), with additional options like radiotherapy for cases with poor response [3]. - The immune remodeling mechanisms behind the efficacy of TNT remain unclear, necessitating further research into the tumor microenvironment (TME) changes induced by this therapy [6]. Group 2: Research Findings - A study published in Cancer Cell reveals that TNT significantly remodels the immune microenvironment in LARC, with CD8+ T cells and endothelial cells interacting as a potential key factor for clinical efficacy [4][10]. - The research utilized single-cell RNA sequencing and spatial transcriptomics to analyze pre- and post-treatment samples, showing that TNT is associated with a reduction in regulatory T cells (Treg) and an increase in IFNG+ CD8+ effector memory T cells, which may enhance complete response rates [6][7]. - The abundance of tumor-infiltrating CD8+ T cells post-TNT correlates with the enrichment of ACKR1+ endothelial cell subpopulations, which are activated by IFNγ released from CD8+ T cells, enhancing their antigen-presenting capabilities [6][7][10]. Group 3: Implications for Clinical Practice - The study provides new insights into optimizing clinical treatment strategies for rectal cancer by elucidating the complex mechanisms of immune response during neoadjuvant therapy [4][10]. - The findings suggest that the quantity of IFNG+ CD8+ T cells and peripheral blood IFNG signaling could serve as markers for response to TNT [8].

Core Viewpoint - The article discusses the role of the p53 R172H mutation in pancreatic ductal adenocarcinoma (PDAC), highlighting its contribution to creating an immunosuppressive tumor microenvironment and reducing the efficacy of immune checkpoint inhibitors (ICIs) [4][13][15]. Group 1: Background on PDAC - PDAC is a highly aggressive cancer characterized by KRAS gene activation mutations and TP53 gene alterations, with TP53 mutations leading to the loss of tumor suppressor function [2][6]. - Approximately 90% of PDAC cases have KRAS activation mutations, while around 70% exhibit changes in the TP53 tumor suppressor gene, indicating the critical role of p53 in genomic protection [7]. Group 2: Research Findings - A study published by MIT researchers reveals that the common p53 mutation, p53 R172H, occupies enhancers of immunosuppressive chemokines (e.g., Cxcl1), stimulating their expression and establishing an immunosuppressive tumor microenvironment in PDAC [3][4][11]. - The study indicates that knocking out the p53 R172H mutation enhances the efficacy of immune checkpoint inhibitors [13][15]. - Mechanistically, p53 R172H enhances Cxcl1 expression by occupying its distal enhancer, with NF-κB being a crucial cofactor for this process [12][15]. Group 3: Implications for Treatment - The findings suggest that p53 R172H promotes tumor growth by regulating cancer cell-specific gene expression programs that shape the tumor microenvironment, thereby inhibiting anti-tumor immune responses [15][16]. - In mouse models of PDAC, tumors lacking p53 R172H showed fewer T cells and higher levels of myeloid-derived suppressor cells (MDSCs), indicating a more favorable immune environment for tumor growth [15].